INT181756

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 4.12
Pain Relevance 0.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
kinase activity (Erbb2) cytoplasm (Erbb2)
Anatomy Link Frequency
MDA-MB-468 1
brain 1
lung 1
Erbb2 (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 6 97.36 Very High Very High Very High
Inflammatory response 1 72.00 Quite High
imagery 16 64.24 Quite High
cINOD 2 62.32 Quite High
aspirin 1 35.12 Quite Low
abdominal pain 1 30.92 Quite Low
positron emission tomography 9 5.00 Very Low Very Low Very Low
cytokine 5 5.00 Very Low Very Low Very Low
agonist 4 5.00 Very Low Very Low Very Low
anesthesia 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lung Cancer 27 99.78 Very High Very High Very High
Breast Cancer 120 99.60 Very High Very High Very High
Cancer 160 99.16 Very High Very High Very High
Apoptosis 38 95.60 Very High Very High Very High
Non-small-cell Lung Cancer 13 95.20 Very High Very High Very High
Disease 5 92.76 High High
Metastasis 28 91.48 High High
Death 8 91.08 High High
Recurrence 12 90.68 High High
Malignant Neoplastic Disease 7 84.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The Her-2 oncogene can be activated by point mutations, gene amplification or over-expression and it is now well accepted that this predicts for a poor outcome in mammalian breast cancer [13,14] and is associated with ER negativity and nodal/brain metastasis.
Positive_regulation (activated) of Her-2 oncogene in brain associated with breast cancer and metastasis
1) Confidence 0.46 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.66 Pain Relevance 0
In contrast, low 89Zr-DFO-trastuzumab accumulation in HER2/neu negative MDA-MB-468 tumors (mean and maximum T/M ratios of 2.26 and 4.15, respectively) was found to occur in accordance with the “enhanced permeation and retention” (EPR) mechanism.[58]
Positive_regulation (accumulation) of HER2/neu in MDA-MB-468 associated with cancer
2) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.70 Pain Relevance 0.03
Therefore, lung tumors with high levels of both EGFR and HER-2 may be appropriate for treatment with lapatinib.
Positive_regulation (levels) of HER-2 in lung associated with lung cancer
3) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 1.03 Pain Relevance 0
EGFR expression has also been linked to activation of ErbB2 in human breast cancers [22].
Positive_regulation (activation) of ErbB2 associated with breast cancer
4) Confidence 0.30 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2254193 Disease Relevance 0.16 Pain Relevance 0
, which transactivates the epidermal growth factor receptor, and epidermal growth factor receptor/c-erbB2 heterodimers, leading to a positive feedback loop in which cells exhibit increased proliferation and reduced apoptosis.
Positive_regulation (transactivates) of c-erbB2 associated with apoptosis
5) Confidence 0.21 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064113 Disease Relevance 1.02 Pain Relevance 0.24
Immunohistochemical stainings for oestrogen and progesterone receptors (Fig 4), GFCDP-15, C-ERB-B2 and CK 7 were positive.
Positive_regulation (positive) of C-ERB-B2
6) Confidence 0.00 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1550421 Disease Relevance 0.55 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox